A Higher Standard
RTI Surgical™ Celebrates First Human Implantation of map3™ Cellular Allogeneic Bone Graft
- Jenny Highlander, APR
- Corporate Communications
- (386) 418-8888
ALACHUA, Fla. (August 12, 2013) — RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, is pleased to announce that the first human implantation of the company’s map3™ Cellular Allogeneic Bone Graft implant was completed last week.
Dr. Franco E. Vigna, M.D., M.P.H., a board-certified orthopedic surgeon with Spine Surgery of Buffalo Niagara and a fellow with the American Academy of Orthopaedic Surgeons, performed the first implantation during a spinal surgery in New York. He used the implant’s chips allograft configuration, one of two configurations that will be available once the implant launches.
“I am excited to have map3 as an option for my patients because of its specific osteogenic and angiogenic properties,” said Vigna, who has been honored as one of the top American orthopedists in spinal care, according to the Consumers’ Research Council of America, 2009. “The future of spine surgery is biologics. We can place the best metal implants but if the bony fusion does not take place, those implants will loosen and the fusion will fail. Having top quality natural biologics along with excellent metal implants gives physicians and patients the best of both worlds.”
Map3 cellular allogeneic bone graft is a natural and safe alternative to autograft. Map3 provides a streamlined approach to bone grafting and supplies the three elements necessary for bone repair—osteogenesis, osteoinduction and osteoconduction—in a single allograft. Map3 incorporates multipotent adult progenitor cell-based (MAPC™-based) technology with stem cells isolated from the same donor as the other bone material. The MAPC technology, licensed from Athersys, Inc. for this orthopedic application, represents a distinctive type of stem cell with recognized angiogenic and immuno-modulatory properties. Once launched, map3 will be available in multiple configurations and sizes, providing bone grafting options for various bone repair, reconstruction and fusion procedures.
“We are thrilled to reach this milestone for map3,” said Brian K. Hutchison, RTI president and CEO. “The MAPC-based technology offers the greatest potential to create high quality, innovative implants for our surgeons and their patients and will greatly enhance our company’s orthobiologics offerings. We anticipate a market release of the implant later this year.”
Surgeons can learn more about the implant and RTI’s other offerings at the North American Spine Society’s (NASS) Annual Meeting in New Orleans, Oct. 9-12. RTI will be exhibiting at booth #621.
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to advancing science, safety and innovation, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.